Professor Nicola Dalbeth
MBChB MD FRACP
Nicola Dalbeth is an academic rheumatologist who leads a clinical and laboratory programme of research in gout, an inflammatory arthritis of major significance to Aotearoa New Zealand. Her work focuses on understanding the impact and mechanisms of disease in gout.
She has been lead investigator in both commercial and investigator-initiated clinical trials in gout. She is a founding member of the Counties Manukau District Health Board Māori Gout Action Group. She chairs the Atlas of Healthcare Variation Gout Expert Advisory Group, and Australia and New Zealand Gout Special Interest Forum. She was the Lead Clinical Advisor for the Gout Clinical Pathways (Greater Auckland Integrated Healthcare Network) and the national bpac Gout Treatment Guidelines. She has served as an Expert Panel member on the American College of Rheumatology Gout Management Guidelines, and is a steering committee member for the OMERACT gout working group and the ACR/EULAR gout classification project.
Research | Current
Clinical research includes clinical trials, imaging studies (using plain radiographs, MRI and three-dimensional CT modeling) to analyze joint damage, studies to investigate the functional impact of gout, and validation of outcome measures in gout. The laboratory work in the Auckland Bone and Joint Research Laboratory involves investigating the cellular and molecular mechanisms of inflammation and joint damage in gout.
Selected publications and creative works (Research Outputs)
- Stewart, S., Keys, M., Brenton-Rule, A., Aiyer, A., Dalbeth, N., & Rome, K. (2018). Characteristics of footwear worn by people with systemic lupus erythematosus: a comparison with age- and sex-matched healthy controls: a pilot study. Journal of Foot and Ankle Research, 11 (1).10.1186/s13047-018-0280-3
- Hutton, J., Fatima, T., Major, T. J., Topless, R., Stamp, L. K., Merriman, T. R., & Dalbeth, N. (2018). Mediation analysis to understand genetic relationships between habitual coffee intake and gout. Arthritis Research & Therapy. 10.1186/s13075-018-1629-5
- Chhana, A., Pool, B., Callon, K. E., Tay, M. L., Musson, D., Naot, D., ... Dalbeth, N. (2018). Monosodium urate crystals reduce osteocyte viability and indirectly promote a shift in osteocyte function towards a proinflammatory and proresorptive state. ARTHRITIS RESEARCH & THERAPY, 2010.1186/s13075-018-1704-y
Other University of Auckland co-authors: David Musson, Ashika Chhana, Bregina Pool, Sue McGlashan, Jillian Cornish, Karen Callon
- Kapetanovic, M. C., Nilsson, P., Turesson, C., Englund, M., Dalbeth, N., & Jacobsson, L. (2018). The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmo Preventive Project cohort in southern Sweden. ARTHRITIS RESEARCH & THERAPY, 2010.1186/s13075-018-1697-6
- Fatima, T., McKinney, C., Major, T. J., Stamp, L. K., Dalbeth, N., Iverson, C., ... Miner, J. N. (2018). The relationship between ferritin and urate levels and risk of gout. ARTHRITIS RESEARCH & THERAPY, 2010.1186/s13075-018-1668-y
- Stewart, S., Rome, K., Eason, A., House, M. E., Horne, A., Doyle, A. J., ... Dalbeth, N. (2018). Predictors of activity limitation in people with gout: a prospective study. Clinical rheumatology, 37 (8), 2213-2219. 10.1007/s10067-018-4110-6
Other University of Auckland co-authors: Anne Horne, Anthony Doyle
- Bourke, S., Taylor, W. J., Doyle, A. J., Gott, M., & Dalbeth, N. (2018). The patient experience of musculoskeletal imaging tests for investigation of inflammatory arthritis: a mixed-methods study. Clinical rheumatology, 37 (8), 2261-2268. 10.1007/s10067-017-3760-0
Other University of Auckland co-authors: Merryn Gott, Anthony Doyle
- Robinson, P. C., & Dalbeth, N. (2018). Febuxostat for the treatment of hyperuricaemia in gout. Expert Opinion on Pharmacotherapy, 1-11. 10.1080/14656566.2018.1498842